WP-1066 is under clinical development by Moleculin Biotech and currently in Phase I for Recurrent Medulloblastoma. According to GlobalData, Phase I drugs for Recurrent Medulloblastoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the WP-1066 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
WP-1066 overview
WP-1066 is under development for the treatment of metastatic melanoma, glioblastoma, head and neck tumors, bladder cancer, renal cancer, ovarian cancer, stomach cancer, pancreatic cancer, brain tumors, pediatric diffuse intrinsic pontine gliomas (DIPG), ependymoma, recurrent or refractory medulloblastoma, acute myeloid leukemia, ocular tumor and recurrent malignant glioma. It is administered through oral and intravenous route. WP-1066 is small molecule Degrasyn drug candidate inhibitor of the PD-L1 and STAT3 pathway. It selectively promotes degradation of vital proteins that are involved in tumor cell proliferation and survival. Degrasyn is an inhibitor of the Janus kinase/signal transducer and activation of transcription (JAK/STAT) pathway. It exerts anti-tumor activity in tumors by inhibiting key growth and survival signaling (JAK/STAT) pathways.
Moleculin Biotech overview
Moleculin Biotech (MBI) is a clinical stage pharmaceutical company. It offers development of novel drugs for oncology. The company’s lead product candidate Annamycin is an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). It also develops WP1066, an immuno-stimulating STAT3 inhibitor, for treatment of brain tumors, pancreatic cancer and AML; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. The company works in collaboration with The University of Texas MD Anderson Cancer Center, and Dermin SP ZOO to develop its product portfolio. MBI is headquartered in Houston, Texas, the US.
For a complete picture of WP-1066’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
